Leto Lab, a biotechnology focused on recobinant protein drugs, has recently completed a series B financing of over RMB100 million yuan. This round of financing was jointly invested by Yijing Capital, Qiaojing Capital and Chang Development.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
